The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 19, 2023
Filed:
Mar. 24, 2017
Applicant:
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
Rachael L. Brake, Natick, MA (US);
Eric H. Westin, Concord, MA (US);
Assignee:
Takeda Pharmaceutical Company Limited, Osaka, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61P 37/06 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2845 (2013.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2839 (2013.01); C07K 16/2878 (2013.01); A61K 2039/507 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01);
Abstract
The invention provides, inter alia, methods of reducing gastrointestinal immune related adverse events, such as colitis and diarrhea, in subjects undergoing an immune treatment, such as an immune oncology treatment, such as anti-CTLA4 antibody and anti-PD-1 antibody combination treatment for melanoma. In certain aspects, the methods encompass administering a therapeutically effective amount of a polypeptide that inhibits MAdCAM-integrin binding, such as an anti-α4β7 integrin antibody, such vedolizumab or a related antibody.